The information contained in this section of the site is intended for US health care professionals and specialty pharmacy representatives only. Click “OK” if you are a health care professional or specialty pharmacy representative.
The OCREVUS Co-pay Program may help eligible commercially insured patients who have been prescribed OCREVUS with their drug co-pays, infusion co-pays or both.
Help with drug costs
Help with infusion costs
If a patient is not eligible for the OCREVUS Co-pay Program, there may be other options for co-pay assistance. Call OCREVUS CONNECTS at (844) OCREVUS (844-627-3887) to speak to a Patient Navigator or visit OCREVUS.com to learn more.
OCREVUS is indicated for the treatment of adult patients with relapsing or primary progressive forms of multiple sclerosis
OCREVUS is contraindicated in patients with active hepatitis B virus infection and/or a in patients with a history of life threatening infusion reaction to OCREVUS.
Management recommendations for infusion reactions depend on the type and severity of the reaction. Permanently discontinue OCREVUS if a life-threatening or disabling infusion reaction occurs
Delay OCREVUS administration in patients with an active infection until the infection is resolved. Vaccination with live-attenuated or live vaccines is not recommended during treatment with OCREVUS and after discontinuation, until B-cell repletion
An increased risk of malignancy, including breast cancer, may exist with OCREVUS.
RMS: The most common adverse reactions (≥10% and >REBIF): upper respiratory tract infections and infusion reactions PPMS: The most common adverse reactions (≥10% and >placebo): upper respiratory tract infections, infusion reactions, skin infections, and lower respiratory track infections
The OCREVUS Prepaid MasterCard® is issued by Comerica Bank pursuant to license by MasterCard International. No cash or ATM access. The card can be used only to purchase prescriptions at participating merchant locations where Debit MasterCard is accepted.